About: Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 May 2002

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в травні 2002 (uk) im Mai 2002 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en mayu de 2002 (ast) scientific article published on 01 May 2002 (en)
publication date	wds:Q74250068-F936F80A-4DC4-48F6-A1FA-64B3DEC704B8
publication date	2002-05-01 00:00:00Z (xsd:dateTime)
author name string	wds:Q74250068-0CDF6DA4-438E-42DC-9A59-50517E41DFD3 wds:Q74250068-0DAB7A2A-1923-46E4-9313-69EA09E38E49 wds:Q74250068-5306EC8D-4279-4775-8CE5-CA6252D0FDB9 wds:Q74250068-65F1E575-0CFC-49BD-AF3B-AE2A3B0AD33B wds:Q74250068-AB536195-AF76-473E-A917-8689C7D6D10B wds:Q74250068-C05BAC80-1926-45DC-A5F0-F31CF61F85C5 wds:Q74250068-CFC028DF-DD54-454F-A209-4BC90CDC951D wds:Q74250068-DB28CBDF-9488-4811-BC1E-9CCEBF33E7B5 wds:Q74250068-E4AA0CFE-BEFE-47B2-B803-83E5643CE88F
author name string	Masahiko Sato John L Vahle James B Nold Jeffery A Engelhardt Gerald G Long Michael S Westmore Jamie K Young Paul C Francis Yanfei Linda
rdfs:label	Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (nl) Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety (en)
skos:prefLabel	Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (nl) Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety (en)
name	Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (nl) Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety (en)
title	wds:Q74250068-3176E1AD-A550-4E73-8801-B213CEF62090
title	Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety (en)
page(s)	wds:Q74250068-C5C2BD9F-88E6-4BBF-81E5-3736093F0F12
page(s)	312-321
instance of	wds:Q74250068-B7412CC7-AB1A-4A1D-B47C-B63E13F82DB4
instance of	scholarly article
PubMed ID	wds:Q74250068-F4DC18B9-3078-420E-9C04-280F7A4D0140
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/12051548
PubMed ID	12051548
published in	wds:Q74250068-63B0ECAA-697F-4136-BADE-A984E08A2B24
published in	Toxicologic Pathology
issue	wds:Q74250068-F977689F-B7A6-4B57-9F22-22E5418556AE
volume	wds:Q74250068-73A3344F-4CB8-419E-ADD8-5FCFC91DDB94
issue	3
volume	30
DOI	wds:Q74250068-13CB38F5-61D2-4649-8E92-0368242E22F4
DOI	http://dx.doi.org/10.1080/01926230252929882
DOI	10.1080/01926230252929882
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q74250068
is cites work of	Drug insight: Existing and emerging therapies for osteoporosis Teriparatide in the treatment of osteoporosis Parathyroid hormone analogues in the treatment of osteoporosis Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis Osteogenesis imperfecta Human umbilical cord blood-derived CD34+ cells reverse osteoporosis in NOD/SCID mice by altering osteoblastic and osteoclastic activities Building bone to reverse osteoporosis and repair fractures The anabolic effects of parathyroid hormone therapy Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Essential role of RSK2 in c-Fos-dependent osteosarcoma development Bisphosphonate treatment for children with disabling conditions New concepts in calcium-sensing receptor pharmacology and signalling Osteosarcomagenesis: modeling cancer initiation in the mouse Of mice and men: divergent risks of teriparatide-induced osteosarcoma The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. Carcinogenicity risk assessment of romosozumab: A review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study PTH(1-34) replacement therapy in a child with hypoparathyroidism caused by a sporadic calcium receptor mutation Osteogenesis Imperfecta: update on presentation and management Potential new drug targets for osteoporosis Clinical update on teriparatide Therapeutic potential of parathyroid hormone Wnt signaling as a therapeutic target for bone diseases Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives Sclerostin Antibody Treatment Improves the Bone Phenotype of Crtap(-/-) Mice, a Model of Recessive Osteogenesis Imperfecta. Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta Low dose parathyroid hormone maintains normal bone formation in adult male rats during rapid weight loss Recombinant full-length parathyroid hormone (1-84). Calcyclin, a Ca2+ ion-binding protein, contributes to the anabolic effects of simvastatin on bone. NELL-1 in the treatment of osteoporotic bone loss. NELL-1 expression in tumors of cartilage Osteoporosis Binge alcohol treatment increases vertebral bone loss following ovariectomy: compensation by intermittent parathyroid hormone Potential role of odanacatib in the treatment of osteoporosis Parathyroid hormone applications in the craniofacial skeleton Teriparatide for osteoporosis: importance of the full course Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation Update on the efficacy, safety, and adherence to treatment of full length parathyroid hormone, PTH (1-84), in the treatment of postmenopausal osteoporosis Safety of parathyroid hormone for the treatment of osteoporosis Malignant myeloma in a patient after treatment for osteoporosis with teriparatide; a rare coincidence Current and emerging treatments for the management of osteogenesis imperfecta. NELL-1 injection maintains long-bone quantity and quality in an ovariectomy-induced osteoporotic senile rat model Assessment of bone quality using finite element analysis based upon micro-CT images American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis Histone deacetylases in skeletal development and bone mass maintenance PTH1-34 alleviates radiotherapy-induced local bone loss by improving osteoblast and osteocyte survival. Intermittent Administration of Parathyroid Hormone [1-34] Prevents Particle-Induced Periprosthetic Osteolysis in a Rat Model PTH prevents the adverse effects of focal radiation on bone architecture in young rats Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate Osteoporosis in paediatric patients with spina bifida

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software